• Entera Bio priced an oversubscribed private placement expected to raise USD 275 million in gross proceeds.
• Led by BVF Partners, with participation from several healthcare-focused investors; closing expected around July 28, 2026.
• Structure includes 122,961,215 ordinary shares at USD 2.04 each, with pre-funded warrants for up to 11,842,695 shares.
• Proceeds expected to extend cash runway into 2030, funding Phase 3 registrational studies for EB613 oral osteoporosis tablet.
• BVF to gain the right to designate two board directors upon closing, subject to standard eligibility requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270830PRIMZONEFULLFEED9798438) on July 27, 2026, and is solely responsible for the information contained therein.